Many basic and clinical studies have demonstrated that atherosclerosis is a chronic inflammatory disease. Although there are many factors affecting atherosclerosis, the role of lymphatic vessels in this disease has been neglected. Traditionally, lymphatic vessels have been considered to be passages for transporting interstitial fluid to the blood circulation. However, as early as the last century, researchers found that there are numerous lymphatic vessels surrounding sites of atherosclerosis; however, the relationship between lymphatic vessels and atherosclerosis is not clear. With further research, lymphatic vessels were determined to be involved in the induction and resolution of arterial inflammation and also to play a positive role in plaque cholesterol transport. There are abundant immune cells around atherosclerosis, and these immune cells not only have a significant impact on plaque formation but also affect local lymphangiogenesis (IAL). This promotion of IAL seems to relieve the progression of atherosclerosis. Therefore, research into the relationship between lymphatic vessels and atherosclerosis is of great importance for improving atherosclerosis treatment. This review highlights what is known about the relationship between lymphatic vessels and atherosclerosis, including the effect of immune cells on IAL, and reverse cholesterol transport. In addition, we present some of our views on the improvement of atherosclerosis treatment, which have significant clinical value in research.
Get full access to this article
View all access options for this article.
References
1.
PollmannC, HägerlingR, KieferF. Visualization of Lymphatic Vessel Development, Growth, and Function. Adv Anat Embryol Cell Biol, 2014; 214:167–186.
2.
LemoleGM. The role of lymphstasis in atherogenesis. Ann Thorac Surg, 1981; 31:290–293.
3.
WaśH.Characterization of markers and growth factors for lymphatic endothelium. Postepy Biochem, 2005; 51:209–214.
4.
HuangLH, ElvingtonA, RandolphGJ. The role of the lymphatic system in cholesterol transport. Front Pharmacol, 2015; 6:182.
5.
WiltingJBJ, ButtlerK, WeichHA. Lymphatics and inflammation. Curr Med Chem, 2009; 16:4581–4592.
6.
XuX, LinH, LvH, ZhangM, ZhangY. Adventitial lymphatic vessels—an important role in atherosclerosis. Med Hypotheses, 2007; 69:1238–1241.
KahnML, RaderDJ. Lymphatics as a new active player in reverse cholesterol transport. Cell Metab, 2013; 17:627–628.
11.
MartelC, LiW, FulpB, et al.Lymphatic vasculature mediates macrophage reverse cholesterol transport in mice. J Clin Invest, 2013; 123:1571–1579.
12.
RovenskáERJ.Lymphatic vessels: Structure and function. Isr Med Assoc J, 2011; 13:762–768.
13.
AlitaloK. The lymphatic vasculature in disease. Nat Med, 2011; 17:1371–1380.
14.
AlitaloK, TammelaT, PetrovaTV. Lymphangiogenesis in development and human disease. Nature, 2005; 438:946–953.
15.
HansenKC, D'AlessandroA, ClementCC, SantambrogioL. Lymph formation, composition and circulation: A proteomics perspective. Int Immunol, 2015; 27:219–227.
16.
KholovaI, DragnevaG, CermakovaP, et al.Lymphatic vasculature is increased in heart valves, ischaemic and inflamed hearts and in cholesterol-rich and calcified atherosclerotic lesions. Eur J Clin Invest, 2011; 41:487–497.
17.
CosoS, BovayE, PetrovaTV. Pressing the right buttons: Signaling in lymphangiogenesis. Blood, 2014; 123:2614–2624.
18.
GerliRSR, WeberE, Aglianó M. Specific adhesion molecules bind anchoring filaments and endothelial cells in human skin initial lymphatics. Lymphology, 2000; 33:148–157.
19.
KeslerCT, LiaoS, MunnLL, PaderaTP. Lymphatic vessels in health and disease. Syst Biol Med, 2013; 5:111–124.
20.
MillerAJDA, PalmerA. The role of the lymphatic system in coronary atherosclerosis. Med Hypotheses, 1992; 37:31–36.
21.
SacchiGWE, CompariniL. Histological framework of lymphatic vasa vasorum of major arteries: An experimental study. Lymphology, 1990; 23:135–139.
22.
XuX, LuH, LinH, et al.Aortic adventitial angiogenesis and lymphangiogenesis promote intimal inflammation and hyperplasia. Cardiovasc Pathol, 2009; 18:269–278.
23.
DrozdzK, JanczakD, DziegielP, et al.Adventitial lymphatics of internal carotid artery in healthy and atherosclerotic vessels. Folia Histochem Cytobiol, 2008; 46:433–436.
24.
KutkutI, MeensMJ, McKeeTA, Bochaton-PiallatML, KwakBR. Lymphatic vessels: An emerging actor in atherosclerotic plaque development. Eur J Clin Invest, 2015; 45:100–108.
25.
ProulxST, LucianiP, DieterichLC, KaramanS, LerouxJC, DetmarM. Expansion of the lymphatic vasculature in cancer and inflammation: New opportunities for in vivo imaging and drug delivery. J Control Release, 2013; 172:550–557.
26.
GrzegorekI, DrozdzK, ChmielewskaM, et al.Arterial wall lymphangiogenesis is increased in the human iliac atherosclerotic arteries: Involvement of CCR7 receptor. Lymphatic Res Biol, 2014; 12:222–231.
27.
RademakersT, van der VorstEP, DaissormontIT, et al.Adventitial lymphatic capillary expansion impacts on plaque T cell accumulation in atherosclerosis. Sci Rep, 2017; 7:45263.
28.
PantS, DeshmukhA, GurumurthyGS, et al.Inflammation and atherosclerosis—revisited. J Cardiovasc Pharmacol Ther, 2014; 19:170–178.
29.
KataruRPLY, KohGY. Interactions of immune cells and lymphatic vessels. Adv Anat Embryol Cell Biol, 2014; 214:107–118.
BalukP, FuxeJ, HashizumeH, et al.Functionally specialized junctions between endothelial cells of lymphatic vessels. J Exp Med, 2007; 204:2349–2362.
32.
NiheiM, OkazakiT, EbiharaS, et al.Chronic inflammation, lymphangiogenesis, and effect of an anti-VEGFR therapy in a mouse model and in human patients with aspiration pneumonia. J Pathol, 2015; 235:632–645.
33.
CorlissBAAM, MunsonJM, PeirceSM, MurfeeWL. Macrophages: An inflammatory link between angiogenesis and lymphangiogenesis. Microcirculation, 2016; 23:95–121.
34.
GuilleminGJ, BrewBJ. Microglia, macrophages, perivascular macrophages, and pericytes: A review of function and identification. J Leukoc Biol, 2004; 75:388–397.
35.
SerhanCN, SavillJ. Resolution of inflammation: The beginning programs the end. Nat Immunol, 2005; 6:1191–1197.
36.
LlodraJ, AngeliV, LiuJ, TroganE, FisherEA, RandolphGJ. Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. Proc Natl Acad Sci U S A, 2004; 101:11779–11784.
37.
ZumstegACG. Myeloid cells and lymphangiogenesis. Cold Spring Harb Perspect Med, 2012; 2:a006494.
38.
JiRC. Macrophages are important mediators of either tumor- or inflammation-induced lymphangiogenesis. Cell Mol Life Sci, 2012; 69:897–914.
39.
HallKL, Volk-DraperLD, FlisterMJ, RanS. New model of macrophage acquisition of the lymphatic endothelial phenotype. PLoS One, 2012; 7:e31794.
40.
BanchereauJSR. Dendritic cells and the control of immunity. Nature, 1998; 392:245–252.
41.
ChistiakovDASI, OrekhovAN, BobryshevYV. Dendritic cells in atherosclerotic inflammation: The complexity of functions and the peculiarities of pathophysiological effects. Front Physiol, 2014; 5:196.
YeZJM, WangS, ZhangJ, SongX, HuangR. Subcutaneous injection of dendritic cells aggravates atherosclerosis in ApoE-knockout mice by activation of TLR4. Mol Med Rep, 2017; 16:6041–6049.
44.
TalO, LimHY, GurevichI, et al.DC mobilization from the skin requires docking to immobilized CCL21 on lymphatic endothelium and intralymphatic crawling. J Exp Med, 2011; 208:2141–2153.
45.
JohnsonLA, ClasperS, HoltAP, LalorPF, BabanD, JacksonDG. An inflammation-induced mechanism for leukocyte transmigration across lymphatic vessel endothelium. J Exp Med, 2006; 203:2763–2777.
46.
Echeverri TiradoLC, YassinLM. B cells interactions in lipid immune responses: Implications in atherosclerotic disease. Lipids Health Dis, 2017; 16:30.
47.
AngeliV, RandolphGJ. Inflammation, lymphatic function, and dendritic cell migration. Lymphatic Res Biol, 2006; 4:217–228.
48.
MasopustD, SchenkelJM. The integration of T cell migration, differentiation and function. Nat Rev Immunol, 2013; 13:309–320.
MartelC, RandolphGJ. Atherosclerosis and transit of HDL through the lymphatic vasculature. Curr Atheroscler Rep, 2013; 15:354.
58.
Escola-GilJC, Lee-RueckertM, SantosD, CedoL, Blanco-VacaF, JulveJ. Quantification of in vitro macrophage cholesterol efflux and in vivo macrophage-specific reverse cholesterol transport. Methods Mol Biol, 2015; 1339:211–233.
59.
AyaoriM. Role of HDL in cholesterol efflux and reverse cholesterol transport. Rinsho Byori, 2016; 64:57–65.
60.
TallAR, Yvan-CharvetL, TerasakaN, PaglerT, WangN. HDL, ABC transporters, and cholesterol efflux: Implications for the treatment of atherosclerosis. Cell Metab, 2008; 7:365–375.
61.
BrunhamLR, HaydenMR. Human genetics of HDL: Insight into particle metabolism and function. Prog Lipid Res, 2015; 58:14–25.
62.
ChauPNY, FieldingCJ, FieldingPE. Mechanism of prebeta-HDL formation and activation. Biochemistry, 2006; 45:3981–3987.
63.
RandolphGJ, MillerNE. Lymphatic transport of high-density lipoproteins and chylomicrons. J Clin Invest, 2014; 124:929–935.
NanjeeMNCC, WongJS, HamiltonRL, OlszewskiWL, MillerNE. Composition and ultrastructure of size subclasses of normal human peripheral lymph lipoproteins: Quantification of cholesterol uptake by HDL in tissue fluids. J Lipid Res, 2001; 42:639–648.
66.
LimHY, ThiamCH, YeoKP, et al.Lymphatic vessels are essential for the removal of cholesterol from peripheral tissues by SR-BI-mediated transport of HDL. Cell Metab, 2013; 17:671–684.
67.
NayakYAK, MutalikS, NayakUY. Lymphatic Delivery of Anti-HIV Drug Nanoparticles. Recent Pat Nanotechnol, 2016; 10:116–127.
68.
MolicaF, MeensMJ, DubrotJ, et al.Pannexin1 links lymphatic function to lipid metabolism and atherosclerosis. Sci Rep, 2017; 7:13706.
69.
MilasanA, JeanG, DallaireF, et al.Apolipoprotein A-I modulates atherosclerosis through lymphatic vessel-dependent mechanisms in mice. J Am Heart Assoc, 2017; 6: pii: e006892.
70.
GüçE, BriquezP, ForetayD, FankhauserMA, HubbellJA, KilarskiWW, SwartzMA.Local induction of lymphangiogenesis with engineered fibrin-binding VEGF-C promotes wound healing by increasing immune cell trafficking and matrix remodeling. Biomaterials, 2017; 131:160–175.
71.
ReddyST, van der VliesAJ, SimeoniE, et al.Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol, 2007; 25:1159–1164.
72.
ZhanX, TranKK, ShenH. Effect of the Poly(ethylene glycol) (PEG) Density on the Access and Uptake of Particles by Antigen-Presenting Cells (APCs) after subcutaneous administration. Mol Pharm, 2012; 9:3442–3451.
73.
ZhuangY, MaY, WangC, et al.PEGylated cationic liposomes robustly augment vaccine-induced immune responses: Role of lymphatic trafficking and biodistribution. J Control Release, 2012; 159:135–142.
74.
VuorioT, NurmiH, MoultonK, et al.Lymphatic vessel insufficiency in hypercholesterolemic mice alters lipoprotein levels and promotes atherogenesis. Arterioscler Thromb Vasc Biol, 2014; 34:1162–1170.
75.
AbouelkheirGRUB, RutkowskiJM. Lymphangiogenesis: Fuel, smoke, or extinguisher of inflammation's fire?. Exp Biol Med, 2017; 242:884–895.
